{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T19:20:39Z","timestamp":1694632839931},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/mjt.0b013e3180ed4273","type":"journal-article","created":{"date-parts":[[2008,5,16]],"date-time":"2008-05-16T07:09:40Z","timestamp":1210921780000},"page":"278-286","source":"Crossref","is-referenced-by-count":1,"title":["Outpatient Management of Chronic Kidney Disease: Proteinuria, Anemia and Bone Disease as Therapeutic Targets"],"prefix":"10.1097","volume":"15","author":[{"given":"Albert","family":"Lam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddharth","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Paparello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-11-20210202","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJM198312223092503","article-title":"Use of single voided urine samples to estimate quantitative proteinuria.","volume":"309","author":"Ginsberg","year":"1983","journal-title":"N Engl J Med"},{"key":"R3-11-20210202","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1046\/j.1523-1755.1998.00874.x","article-title":"Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies: Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN).","volume":"53","author":"Ruggenenti","year":"1998","journal-title":"Kidney Int"},{"key":"R4-11-20210202","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1046\/j.1523-1755.2003.00868.x","article-title":"Proteinuria and the risk of developing end-stage renal disease.","volume":"63","author":"Iseki","year":"2003","journal-title":"Kidney Int"},{"key":"R5-11-20210202","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"R6-11-20210202","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S0272-6386(03)00742-X","article-title":"Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway.","volume":"42","author":"Romundstad","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R7-11-20210202","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0002-8703(84)90763-4","article-title":"The prognostic significance of proteinuria: the Framingham study.","volume":"108","author":"Kannel","year":"1984","journal-title":"Am Heart J"},{"key":"R9-11-20210202","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1046\/j.1523-1755.2001.0590041211.x","article-title":"Renoprotection: One or many therapies?","volume":"59","author":"Hebert","year":"2001","journal-title":"Kidney Int"},{"key":"R10-11-20210202","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.ASN.0000018401.82863.FD","article-title":"Smoking and the kidney.","volume":"13","author":"Orth","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"R11-11-20210202","doi-asserted-by":"crossref","first-page":"754","DOI":"10.7326\/0003-4819-123-10-199511150-00003","article-title":"Blood pressure control, proteinuria, and the progression of renal disease: The Modification of Diet in Renal Disease Study.","volume":"123","author":"Peterson","year":"1995","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"R12-11-20210202","first-page":"B54","article-title":"Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.","volume":"23","author":"Estacio","year":"2000","journal-title":"Diabetes Care"},{"key":"R13-11-20210202","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"R14-11-20210202","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group.","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"R15-11-20210202","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jama.1994.03510280037029","article-title":"Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria: European Microalbuminuria Captopril Study Group.","volume":"271","author":"Viberti","year":"1994","journal-title":"JAMA"},{"key":"R16-11-20210202","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy.","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"R17-11-20210202","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency: The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group.","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"R18-11-20210202","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(98)10363-X","article-title":"Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.","volume":"354","author":"Ruggenenti","year":"1999","journal-title":"Lancet"},{"key":"R19-11-20210202","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"R20-11-20210202","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"R21-11-20210202","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","article-title":"Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data.","volume":"48","author":"MacKinnon","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R22-11-20210202","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study.","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabet Med"},{"key":"R23-11-20210202","first-page":"S182","article-title":"K\/doqi clinical practice guidelines for anemia of chronic kidney disease.","volume":"37","author":"National Kidney","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R24-11-20210202","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1053\/ajkd.2001.27699","article-title":"Anemia: an early complication of chronic renal insufficiency.","volume":"38","author":"Kazmi","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R25-11-20210202","first-page":"S98","article-title":"The long-term effects of recombinant human erythropoietin on the cardiovascular system.","volume":"38","author":"Eschbach","year":"1992","journal-title":"Clin Nephrol"},{"key":"R26-11-20210202","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0272-6386(97)90335-8","article-title":"Cardiovascular effects of recombinant human erythropoietin in pre-dialysis patients.","volume":"29","author":"Portoles","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"R27-11-20210202","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1038\/ki.1996.201","article-title":"Outcome and risk factors of ischemic heart disease in chronic uremia.","volume":"49","author":"Parfrey","year":"1996","journal-title":"Kidney Intl"},{"key":"R28-11-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/ki.1991.20","article-title":"rHuEPO treatment improves brain and cognitive function of anemic dialysis patients.","volume":"39","author":"Marsh","year":"1991","journal-title":"Kidney Intl"},{"key":"R29-11-20210202","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0272-6386(95)90122-1","article-title":"Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients.","volume":"25","author":"Revicki","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"R30-11-20210202","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.ajkd.2005.05.018","article-title":"Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.","volume":"46","author":"Collins","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R31-11-20210202","doi-asserted-by":"crossref","first-page":"s39","DOI":"10.1053\/ajkd.2000.19930","article-title":"Anemia management in patients with chronic renal insufficiency.","volume":"36","author":"Kausz","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R32-11-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00041552-199503000-00008","article-title":"The use of recombinant human erythropoietin in pre-dialysis patients.","volume":"4","author":"Besarab","year":"1995","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R33-11-20210202","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1053\/ajkd.2001.29264","article-title":"Novel erythropoiesis stimulating protein for managing the anemia of chronic kidney disease.","volume":"38","author":"Nissenson","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R34-11-20210202","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1681\/ASN.V10112392","article-title":"Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients.","volume":"10","author":"Macdougall","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"R35-11-20210202","first-page":"A258","article-title":"Novel erythropoiesis stimulating protein (NESP) for the treatment of renal anemia.","volume":"9","author":"Macdougall","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"Suppl 3","key":"R36-11-20210202","first-page":"S11","article-title":"K\/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease.","volume":"47","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R37-11-20210202","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R38-11-20210202","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia.","volume":"355","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"R39-11-20210202","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Intl"}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00045391-200805000-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T19:13:44Z","timestamp":1631301224000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00045391-200805000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3180ed4273","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}